KR101059844B1 - Functional assistant tape for treating musculoskeletal using zirconia and method for manufacturing the same - Google Patents
Functional assistant tape for treating musculoskeletal using zirconia and method for manufacturing the same Download PDFInfo
- Publication number
- KR101059844B1 KR101059844B1 KR1020100015166A KR20100015166A KR101059844B1 KR 101059844 B1 KR101059844 B1 KR 101059844B1 KR 1020100015166 A KR1020100015166 A KR 1020100015166A KR 20100015166 A KR20100015166 A KR 20100015166A KR 101059844 B1 KR101059844 B1 KR 101059844B1
- Authority
- KR
- South Korea
- Prior art keywords
- zirconia
- particles
- tape
- yttria
- stabilized
- Prior art date
Links
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 239000002245 particle Substances 0.000 claims abstract description 49
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000000919 ceramic Substances 0.000 claims abstract description 16
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 16
- 239000004332 silver Substances 0.000 claims abstract description 16
- 229910052709 silver Inorganic materials 0.000 claims abstract description 16
- 229940070527 tourmaline Drugs 0.000 claims abstract description 16
- 229910052613 tourmaline Inorganic materials 0.000 claims abstract description 16
- 239000011032 tourmaline Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000002131 composite material Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 229920000742 Cotton Polymers 0.000 claims abstract description 5
- 239000004744 fabric Substances 0.000 claims abstract description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract 8
- RUDFQVOCFDJEEF-UHFFFAOYSA-N yttrium(III) oxide Inorganic materials [O-2].[O-2].[O-2].[Y+3].[Y+3] RUDFQVOCFDJEEF-UHFFFAOYSA-N 0.000 claims description 27
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 14
- 239000000853 adhesive Substances 0.000 claims description 11
- 230000001070 adhesive effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 9
- 229910001233 yttria-stabilized zirconia Inorganic materials 0.000 claims description 8
- 239000012767 functional filler Substances 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 6
- 238000005520 cutting process Methods 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 abstract description 7
- 150000001450 anions Chemical class 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 239000004848 polyfunctional curative Substances 0.000 abstract 1
- 238000010186 staining Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 description 38
- 210000003205 muscle Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- -1 platinum ions Chemical class 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000004887 air purification Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000012191 relaxation of muscle Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
- Adhesives Or Adhesive Processes (AREA)
Abstract
Description
본 발명은 지르코니아 나노입자를 이용한 근골격계 질환 치료보조용 테이프 및 그 제조방법에 관한 것으로, 더욱 상세하게는 인공 골두, 임플란트와 같은 치아재료 등의 생체재료로 사용되어지고 있는 지르코니아 ,음이온방출 세라믹 및 바인더를 이용하여 원적외선 방사, 음이온 방출, 내오염성 및 항균성이 확보된 근골격계 치료보조용 테이프 및 그 제조방법에 관한 것이다.The present invention relates to a tape for treating musculoskeletal disorders using zirconia nanoparticles and a method for manufacturing the same, and more particularly, to zirconia, anion-releasing ceramics and binders, which are used as biomaterials such as dental materials such as artificial heads and implants. The present invention relates to a musculoskeletal treatment aid tape having far-infrared radiation, anion release, fouling resistance and antibacterial property, and a method of manufacturing the same.
본 발명은 각종 근골격계 질환이 발병하였을 때 그 치료 방법중의 하나로 외 과적인 수술 없이 간단하게 치료받을 수 있는 방법으로 각광받고 있는 테이프 보조치료요법에 사용될 수 있는 인체에 유익한 원적외선 방사 및 음이온 방출, 내오염성 및 내 화학성이 부여된 지르코니아를 이용한 근골격계 질환 치료보조용 테이프에 관한 것이다.The present invention is one of the methods of treatment when various musculoskeletal diseases develop, far infrared radiation and anion emission, which is beneficial to the human body, which can be used for tape adjuvant therapy, which can be easily treated without surgery. The present invention relates to a tape for treating musculoskeletal disorders using zirconia imparted with contaminants and chemical resistance.
일반적으로, 현대인들은 실생활에서 각종 많은 근골격계 질환이 발병하고 있는 상태이다. 외과적인 수술 및 입원 치료 등 실생활과 단절된 상태에서의 치료 방법보다는, 그 치료방법이 간단하고도 효과적이며 실생활이 계속적으로 가능한 치료방법들이 각광받고 있는 현실에서 그 치료방법 중의 하나가 테이핑 치료요법이다. In general, modern people are in a state of developing many kinds of musculoskeletal diseases in real life. One of the treatments is taping therapy in the reality that the treatment methods are simple and effective, and the real-life continuous treatment methods are in the spotlight rather than the treatment methods that are disconnected from the real life such as surgical surgery and hospitalization treatment.
테이핑 치료의 원리를 살펴보면 다음과 같다.The principle of taping treatment is as follows.
테이핑 치료의 원리는 테이프가 약 30%의 신축성을 가지고 있으므로 테이프를 붙인 피부 부위의 테이프에 주름이 생기는데 이는 피부가 테이프에 의해 들려지는 것을 의미한다(약 10 microns). 그로 인해 근육과 피부 사이에 공간이 생기게 되며 그 공간으로 혈액과 림프액의 순환이 증가하여 근육이 이완되고, 또 통증 수용기에 대한 압력의 감소로 인해 통증이 감소하게 되어 정상적인 신진대사 작용이 이루어져 근육의 운동기능이 되살아나게 됨으로써 정상적인 신체활동을 회복하게 하는 것이다.The principle of taping treatment is that the tape has about 30% elasticity, which causes wrinkles in the tape on the skin where the tape is attached, which means the skin is lifted by the tape (about 10 microns). As a result, a space is created between the muscle and the skin, and the circulation of blood and lymph fluid increases to relax the muscle, and the pain decreases due to the decrease in pressure on the pain receptor, which leads to normal metabolism. By reviving the motor function is to restore normal physical activity.
통증 조절 기능에 관하여 좀 더 구체적으로 설명하면, 피부에 붙여진 테이프는 피부에 물리적인 자극을 지속적으로 가하게 되며 이 자극은 근육에 있는 통증을 전달하는 섬유보다 먼저 척수에 도달하여 통증의 전달을 억제하는 기능을 함으로써 통증을 감소(게이트조절이론; Gate control theory)시키는 역할을 한다. In more detail, the tape on the skin continuously applies a physical stimulus to the skin, which causes it to reach the spinal cord before the fibers that deliver the pain in the muscles, thereby inhibiting the transmission of the pain. It functions to reduce pain (gate control theory).
상기와 같은 테이핑 치료의 효과를 살펴보면 다음과 같다.Looking at the effects of the taping treatment as described above are as follows.
테이핑치료의 효과로는 혈액, 림프액, 조직액 등의 순환을 원활하게 하여 근육을 이완시켜 주고 근육의 기능을 정상화시켜 주며(근방추 반사작용), 통증을 완화시켜줄 뿐만 아니라 치료효과도 지속시켜 준다. 또한 근육과 건의 지나친 수축과 이완을 예방하여 골지건(Golgi tendon)에 자극으로 근육과 건의 과도한 수축 및 긴장 조절, 자세조절, 및 신체의 평형조절에도 중요한 효과를 나타낸다. 마지막 효과로는 근육의 기능을 회복함으로써 관절이 정상위치에서 활동할 수 있게 되며 이로 인한 관절 가동범위의 증가는 혈액순환의 증가를 가져와 2차 손상의 예방 및 퇴행성 관절의 예방과 지연을 들 수 있다. The effect of taping treatment is to smooth the circulation of blood, lymph, tissue fluid, etc. to relax the muscles, normalize the function of the muscles (muscleus reflex), to relieve pain and to maintain the therapeutic effect. In addition, by preventing excessive contraction and relaxation of muscles and tendons, Golgi tendon stimulates excessive contraction and tension of muscles and tendons, postural control, and body balance. The final effect is to restore the function of the muscles to allow the joints to work in the normal position, resulting in increased range of motion resulting in increased blood circulation, preventing secondary damage and preventing and delaying degenerative joints.
원적외선의 경우 빛의 파장이 인체의 피부에 어떠한 침해 작용 없이 피부 속 깊숙이 침투하여 인체세포를 구성하는 분자와 작용하여 각종 영양을 분해하여 영양의 균형을 유지하는 공명효과, 스스로 열을 내게 하는 특성이 있는 온열효과, 노폐물 배출을 하게 하는 증화 효과, 혈액순환을 촉진하는 자정 및 정혈효과가 탁월한 것으로 이미 알려져 있다. In the case of far-infrared light, the wavelength of light penetrates deeply into the skin without any invading effect on the human body, and works with molecules that make up human cells. It is already known for its warming effect, the increase in waste discharge, the midnight and blood circulation effects that promote blood circulation.
음이온은 공기정화, 먼지 제거, 살균작용, 인체 저항력증가 등이 뛰어난 것으로 알려져 있어 원적외선 및 음이온 방출 소재를 각종 실생활용품이나 건축내외장재에 도료로 사용하는 연구가 활발하게 이루어지고 있다. Negative ions are known to be excellent in air purification, dust removal, sterilization, and increased resistance to human body. Therefore, research on using far-infrared rays and anion-releasing materials as paints for various real life products and interior and exterior materials for buildings is being actively conducted.
기존의 치료용 테이프는 통증이 있는 근육의 시작부위와 끝 부위를 정확하게 찾아서 근육의 크기, 형태 및 길이에 따라 테이프의 적절한 긴장도를 감안하여 붙여야 효과가 있으나, 본 발명에서 이루고자 하는 특징은 위의 테이핑 원칙대로 하면 최적의 효과를 거둘 수 있지만 원적외선과 음이온의 방출로 인해 붙이는 특별한 방법에 관계없이도 일정의 치료 효과를 나타낼 수 있다. Existing therapeutic tape is effective to find the beginning and end of the painful muscle accurately and to apply in consideration of the appropriate tension of the tape according to the size, shape and length of the muscle, but the characteristics to achieve in the present invention is the above taping In principle, the optimum effect can be achieved, but due to the release of far-infrared rays and negative ions, it can produce a certain therapeutic effect regardless of the special method of attachment.
한편, 각종 세라믹에서 원적외선 방사, 음이온 방출이 되고 있다는 것이 알려진 후부터 각종 세라믹을 각종 수지물 등에 혼합하여 실생활제품에 응용하는 연구가 활발하게 진행되고 있다. 그러나 이러한 종래의 응용하는 기술들은 각각 그 특성에 따라서 적용범위가 한정되어 있거나, 인체 무해성 여부가 판별되지 못하였기 때문에 그 사용범위가 극히 제한되는 문제점이 있었다. On the other hand, since it is known that far-infrared radiation and anion emission are emitted from various ceramics, studies are being actively conducted to mix various ceramics with various resin materials and apply them to real life products. However, these conventional applications have a problem that the scope of use is extremely limited because the application range is limited depending on the characteristics of each, or the harmlessness of the human body is not determined.
본 발명이 해결하고자 하는 과제는 생체 재료로 사용되고 있는 지르코니아 나노입자의 생체친화성과 높은 원적외선 방사특성, 항균특성, 내화학성을 이용하여 무기질 도막을 형성할 수 있는 근골격계 질환 치료용 지르코니아 테이프를 제조할 수 있는 기술을 제공하는 것이다.The problem to be solved by the present invention is to produce a zirconia tape for treating musculoskeletal disorders that can form an inorganic coating film using the biocompatibility of the zirconia nanoparticles used as a biomaterial and high far-infrared radiation characteristics, antibacterial properties, chemical resistance Is to provide the technology.
본 발명의 친환경 지르코니아 도료는 2~10 wt% 이트리아로 안정화된 지르코니아 나노입자(20~50nm)분말 1~10wt%, 기능성을 부여하기 위한 분말 및 액상 충진제 1~5 wt%, 그리고 점착용 바인더 85~98wt% 로 혼합 분산되어 있는 것을 특징으로 한다. Eco-friendly zirconia paint of the present invention is 1 ~ 10wt% zirconia nanoparticles (20 ~ 50nm) powder stabilized with 2 ~ 10 wt% yttria, powder and liquid filler 1 ~ 5 wt%, and adhesive binder for imparting functionality It is characterized by being mixed and dispersed at 85 ~ 98wt%.
상기와 같은 과제를 달성하기 위한 본 발명 근골격계 질환 치료용 지르코니아 테이프는, 2~10wt%의 이트리아로 안정화된 지르코니아 20~50nm 나노입자가 테이프에 균일하게 혼합 분산 도포된 것을 특징으로 한다. Zirconia tape for treating musculoskeletal disorders of the present invention for achieving the above object is characterized in that the zirconia 20 ~ 50nm nanoparticles stabilized with 2 to 10wt% of yttria uniformly mixed dispersion coating on the tape.
또한 본 발명 근골격계 질환 치료용 지르코니아 테이프 제조방법은, a) 2~10wt% 이트리아로 안정화된 지르코니아 나노입자(20~50nm) 분말을 준비하는 단계와, b) 점착용 바인더에 상기 a)에 준비된 지르코니아 나노입자, 기능성을 부여하기 위한 분말 및 액상 충진제 등을 첨가하여 혼합 분산시키는 단계와, c) 상기 b)단계의 결과물에 경화제를 첨가하고 교반하여 상기 지르코니아 입자와 기능성 분말 및 액상 충진제 분산물을 테이프용 면직물에 도포시키는 단계와, d) 상기 c)단계의 결과물을 건조 후 재단하여 숙성시켜 테이프를 완성하는 단계를 포함하는 근골격계 질환 치료용 지르코니아 테이프 제조방법이다.In another aspect, the present invention provides a method for preparing zirconia tape for treating musculoskeletal disorders, the method comprising the steps of: a) preparing zirconia nanoparticles (20-50 nm) powder stabilized with 2-10 wt% yttria, and b) prepared in a) in an adhesive binder. Adding and dispersing zirconia nanoparticles, powders and liquid fillers for imparting functionality, and c) adding and stirring a curing agent to the resultant of step b) to disperse the zirconia particles, functional powders and liquid filler dispersions. A method of manufacturing a zirconia tape for treating musculoskeletal disorders, comprising: applying to a cotton fabric for tape, and d) cutting and aging the resultant of step c) to complete the tape.
상기와 같이 구성되는 본 발명은 지르코니아 나노입자를 사용하여 테이프에 도포막을 형성함으로써, 지르코니아의 생체 친화성과 높은 원적외선 방사특성, 항균특성, 내화학성을 부여하여 인체에 무해하며 친환경적인 기능성 근골격계 질환 치료용 지르코니아 테이프를 만들 수 있는 효과가 있다.The present invention constituted as described above forms a coating film on the tape using zirconia nanoparticles, thereby giving bio-compatibility of zirconia and high far-infrared radiation characteristics, antimicrobial properties, chemical resistance, harmless to the human body, and eco-friendly for treating functional musculoskeletal diseases Has the effect of making zirconia tape.
도 1은 본 발명에 따른 근골격계 질환 치료보조용 지르코니아 테이프 제조방법의 제조공정 순서도.1 is a manufacturing process flow chart of the zirconia tape manufacturing method for the treatment of musculoskeletal disorders according to the present invention.
이하, 상기에서 기술한 바와 같이 구성된 본 발명 근골격계 질환 치료용 지르코니아 테이프 및 그 제조방법의 바람직한 실시 예를 첨부한 도면을 참조하여 상세히 설명하면 다음과 같다.Hereinafter, with reference to the accompanying drawings a preferred embodiment of the zirconia tape for treating musculoskeletal disorders of the present invention configured as described above and a manufacturing method thereof will be described in detail as follows.
도 1은 본 발명 근골격계 질환 치료용 지르코니아 테이프 제조방법의 바람직한 실시 예에 따른 제조 공정 순서도이다.1 is a manufacturing process flow chart according to a preferred embodiment of the zirconia tape manufacturing method for treating musculoskeletal disorders of the present invention.
도 1을 참조하면 본 발명 근골격계 질환 치료용 지르코니아 테이프 제조방법의 바람직한 실시예는, 이트리아로 안정화된 지르코니아 나노입자를 제조하는 단계(S10)와, 상기 지르코니아 나노입자와 함께 입경이 1 내지 2nm인 은 또는 백금 나노입자 또는 토르말린 등 기능성 충진제 분말을 1가지 이상 점착용 바인더에 혼합 분산시켜 세라믹 복합체를 형성시키는 단계(S20)와, 상기 지르코니아 나노입자와 기능성 충진제 분말입자가 분산 혼합된 세라믹 복합체에 경화제를 혼합하여 교반시키는 단계(S30)를 포함하고, 상기 단계들을 통해 형성된 세라믹 복합체 혼합물을 이형지에 도포하고, 건조시킨 후 테이프용 면직물에 도포시키는 단계(S40)와, 상기 테이프를 재단 후 숙성실에서 48시간 이상 숙성시키는 단계(S50)를 포함한다.Referring to Figure 1, a preferred embodiment of the zirconia tape manufacturing method for treating musculoskeletal disorders of the present invention is to prepare a zirconia nanoparticles stabilized with yttria (S10), and the particle diameter of 1 to 2nm with the zirconia nanoparticles Forming a ceramic composite by mixing and dispersing functional filler powder such as silver or platinum nanoparticles or tourmaline in at least one adhesive binder (S20), and a curing agent in a ceramic composite in which the zirconia nanoparticles and the functional filler powder particles are dispersed Mixing and stirring (S30), and applying the ceramic composite mixture formed through the steps to a release paper, drying and applying the cotton fabric for tape (S40), and cutting the tape in a aging room after cutting 48 Aging over time (S50) is included.
먼저, S10단계에서는 지르코니아를 이트리아(Y2O3)로 안정화시킨다. 상기 이트리아로 안정화된 지르코니아 나노입자의 일실시 제조예를 보다 상세히 설명하면 다음과 같다.First, in step S10, zirconia is stabilized with yttria (Y 2 O 3 ). Hereinafter, an embodiment of the zirconia nanoparticles stabilized with yttria will be described in detail.
원료물질 혼합 수용액을 준비하는 단계(S11)와, 상기 원료물질 혼합 수용액을 가열하여 슬러리 상태에서 이트리아로 안정화된 지르코니아 나노입자를 획득하는 단계(S12), 상기 이트리아로 안정화된 지르코니아 나노입자를 포함하는 슬러리를 세정하고, 필터링하여 습체 상태의 이트리아로 안정화된 지르코니아 나노입자를 획득하는 단계(S13)와, 상기 습체 상태의 이트리아로 안정화된 지르코니아 나노입자를 건조시켜, 이트리아로 안정화된 지르코니아 나노입자 분말을 획득하는 단계(S14)를 포함하여 구성된다. Preparing a mixed solution of raw material (S11), and obtaining the zirconia nanoparticles stabilized with yttria in the slurry state by heating the mixed solution of the raw material (S12), the zirconia nanoparticles stabilized with the yttria Washing and filtering the slurry including the step of obtaining a zirconia nanoparticles stabilized with yttria in the wet state (S13), and drying the zirconia nanoparticles stabilized with the yttria in the wet state, the yttria stabilized It comprises a step (S14) to obtain a zirconia nanoparticle powder.
상기에서 설명한 이트리아로 안정화된 지르코니아 나노입자 제조의 예를 보다 구체적으로 설명하면, 먼저, S11단계에서는 원료물질인 ZrOCl2ㆍ8H20와, YClㆍ6H20를 물과 수산화칼륨(KOH)를 혼합한다. 상기 물과 수산화칼륨의 양은 반응에서 중요하지 않으며, ZrOCl2ㆍ8H20와 YClㆍ6H20의 혼합중량비가 90:10 내지 98:2가 되도록 한다. 이와 같은 혼합으로 ZrOCl2와 YCl3 혼합용액을 얻을 수 있게 된다.The concrete example of the production of yttria-stabilized zirconia nanoparticles described above will be described in more detail. First, in step S11, ZrOCl 2 8H 2 0 and YCl 6H 2 0, which are raw materials, are replaced with water and potassium hydroxide (KOH). Mix it. The amount of water and potassium hydroxide is not critical in the reaction, so that the mixed weight ratio of ZrOCl 2 · 8H 2 0 and YCl.6H 2 0 is 90:10 to 98: 2. This mixing allows a ZrOCl 2 and YCl 3 mixed solution to be obtained.
그 다음, S12단계에서는 상기 S11단계에서 얻은 혼합용액을 150 내지 200℃의 온도에서 24시간 가열하여, 슬러리 상태 내에서 이트리아로 안정화된 지르코니아를 얻을 수 있게 된다.Next, in step S12, the mixed solution obtained in step S11 is heated at a temperature of 150 to 200 ° C. for 24 hours to obtain zirconia stabilized with yttria in a slurry state.
그 다음, S13단계에서는 상기 이트리아로 안정화된 지르코니아 나노입자를 포함하는 슬러리를 물로 세정하고, 필터링하여 습체 상태의 이트리아로 안정화된 지르코니아 나노입자를 획득한다.Next, in step S13, the slurry including the yttria stabilized zirconia nanoparticles is washed with water and filtered to obtain zirconia nanoparticles stabilized with yttria in the wet state.
그 다음, S14단계에서는 상기 습체 상태의 이트리아로 안정화된 지르코니아 나노입자를 100℃에서 24시간 건조시켜, 이트리아로 안정화된 입경이 20 ~ 50nm인 지르코니아 나노입자 분말을 획득한다. 획득된 이트리아로 안정화된 지르코니아 나노입자 분말에는 지르코니아 나노 입자가 90 내지 98wt%, 이트리아가 2 ~10 wt% 포함되어 있다.Next, in step S14, the zirconia nanoparticles stabilized with yttria in the wet state are dried at 100 ° C. for 24 hours to obtain zirconia nanoparticle powders having a yttria stabilized particle diameter of 20 to 50 nm. The obtained zirconia nanoparticle powder stabilized with yttria contains 90 to 98 wt% of zirconia nanoparticles and 2 to 10 wt% of yttria.
그 다음, S20단계에서는 상기 획득된 지르코니아 나노입자와, 기능성 충진 분말을 함께 점착성 바인더에 혼합시켜 분산시킨다. 이때 기능성 충진 분말로는 토르말린 입자가 사용되며 기능에 따라 입경이 1 내지 2nm인 은 또는 백금 나노입자가 1가지 이상 사용될 수 있다.Next, in step S20, the obtained zirconia nanoparticles and the functional filler powder are mixed together and dispersed in an adhesive binder. In this case, tourmaline particles are used as the functional filling powder, and one or more silver or platinum nanoparticles having a particle diameter of 1 to 2 nm may be used depending on the function.
상기 은, 백금 나노입자는 물리적인 분쇄 또는 산에 녹아 있는 은, 백금이온을 환원시켜 얻을 수 있으며, 입경이 1nm ~ 2nm인 은, 백금 나노입자이면 그 제조 방법에 무관하게 본 발명에서 사용할 수 있다.The silver and platinum nanoparticles can be obtained by physically grinding or reducing silver and platinum ions dissolved in an acid, and silver and platinum nanoparticles having a particle diameter of 1 nm to 2 nm can be used in the present invention irrespective of the preparation method thereof. .
상기 기능성 충진제로 사용된 토르말린 분말은 입경이 0.1~100㎛ 입자이면 그 제조 방법에 무관하게 본 발명에서 사용할 수 있다.The tourmaline powder used as the functional filler can be used in the present invention irrespective of the preparation method if the particle size is 0.1-100 μm particles.
상기 이트리아로 안정화된 지르코니아 나노입자와 토르말린 입자의 혼합분말의 중량비는 70:30 ~ 50:50이며 바람직한 혼합비는 55:45이다. 또한, 상기 혼합분말 내에서의 은 또는 백금입자를 기능성 충진제로 첨가할 경우 이트리아로 안정화된 지르코니아 나노입자와 은, 백금 나노입자 및 토르말린의 중량비는 70:5:5:20 내지 50:0.001:0.001:49.998 이며, 바람직하게는 55:0.1:0.1:44.8의 중량비로 혼합 분산한다.The weight ratio of the mixed powder of the yttria stabilized zirconia nanoparticles and tourmaline particles is 70:30 ~ 50:50 and the preferred mixing ratio is 55:45. In addition, when the silver or platinum particles in the mixed powder is added as a functional filler, the weight ratio of the yttria stabilized zirconia nanoparticles, silver, platinum nanoparticles, and tourmaline is 70: 5: 5: 20 to 50: 0.001: It is 0.001: 49.998, Preferably it mix-disperses in the weight ratio of 55: 0.1: 0.1: 44.8.
상기 점착용 바인더는 Acrylic Polymer, Ethyl Acetate, PVB(PolyVinyl Butyral), PVP(PolyVinyl Pyrrolidone), PVA(PolyVinyl Acetate) 또는 PEG(Poly Ethylene Glycol)를 사용할 수 있다.The adhesive binder may be acrylic polymer, ethyl acetate, polyvinyl butyral (pvb), polyvinyl pyrrolidone (pvp), polyvinyl acetate (pva) or poly ethylene glycol (egg).
그 다음, S30단계에서는 상기 점착용 바인더에 혼합되어 분산된, 이트리아로 안정화된 지르코니아 나노입자, 은, 백금, 토르말린 입자로 이루어진 세락믹 복합체 혼합물에 경화제를 교반하여 혼합시킨다.Next, in step S30, the curing agent is mixed and mixed with the ceramic composition mixture composed of yttria stabilized zirconia nanoparticles, silver, platinum, and tourmaline particles, which are mixed and dispersed in the adhesive binder.
상기 세라믹 복합체 분말과 바인더의 혼합비는 2:98 내지 10:90이며, 바람직하게는 5:95이다. 상기 경화제는 이소시아네이트계 화합물로서, NCO화합물 35~50%, 에틸아세테이트 50~70%로 이루어지고, 작업시간과 환경에 따라 적정량, 예컨대 바인더 혼합물의 2~4%를 첨가한다. 혼합 시는 상기 두 재료를 충분하게 혼합할 수 있는 시간(100Kg 기준 약 1시간)이 필요하며, 상기 두 재료를 고르고 충분하게 혼합 할 수 있는 장비라면 어떤 장비도 무관하다.The mixing ratio of the ceramic composite powder and the binder is 2:98 to 10:90, preferably 5:95. The curing agent is an isocyanate compound, which is composed of 35 to 50% of NCO compound and 50 to 70% of ethyl acetate, and an appropriate amount, such as 2 to 4% of the binder mixture, is added depending on the working time and environment. Mixing requires a time (about 1 hour at 100 Kg) to sufficiently mix the two materials, and any equipment may be used as long as the equipment can evenly and sufficiently mix the two materials.
그 다음, S40단계에서는 교반된 테이프용 원료를 이형지(박리지)에 50g/m2 정도의 아크릴 PSA-4800을 넓게 펼쳐 바른 후 건조기를 통과시켜 건조시킨 후 테이프용 면직물을 합지시킨다. 이때 건조온도는 80 내지 150℃ 이며, 바람직하게는 120℃이다.Then, in step S40, the raw material for agitated tape is widely spread on 50g / m 2 of acrylic PSA-4800 on a release paper (paper), dried through a dryer, and then laminated with a cotton fabric for tape. At this time, the drying temperature is 80 to 150 ℃, preferably 120 ℃.
그 다음, S50단계에서는 건조된 테이프를 규격대로 재단 후 숙성실에서 숙성시킨다. 이때 숙성시간은 24 내지 72시간이며 숙성온도는 40 내지 80℃이고, 바람직하게는 60℃에서 48시간 숙성이다.Next, in step S50, the dried tape is cut to size and aged in a aging room. At this time, the aging time is 24 to 72 hours and the aging temperature is 40 to 80 ℃, preferably at 60 ℃ 48 hours aging.
상기와 같이 구성되는 본 발명 근골격계 질환 치료용 지르코니아 테이프 제조의 예를 보다 구체적으로 설명하면 다음과 같다.When explaining the example of the production of zirconia tape for treating musculoskeletal disorders of the present invention configured as described above in more detail.
먼저, 이트리아로 안정화된 지르코니아 나노입자 분말 50g을 준비한다. 이 때 지르코니아 나노입자 분말 50g은 지르코니아 나노입자 47.5g과 이트리아 나노입자 2.5g으로 이루어진다. 상기 지르코니아 나노입자의 입경은 20내지 40nm이다. 그리고 직경이 1 내지 10㎛인 토르말린 분말 50g을 준비한다. 준비된 50g의 이트리아 안정 지르코니아 나노입자 분말과 50g의 토르말린 입자를 고속 교반 분산장비를 이용하여 혼합시킨다.First, 50 g of zirconia nanoparticle powder stabilized with yttria is prepared. At this time, 50g of zirconia nanoparticle powder is composed of 47.5g of zirconia nanoparticle and 2.5g of yttria nanoparticle. The particle size of the zirconia nanoparticles is 20 to 40nm. Then, 50 g of tourmaline powder having a diameter of 1 to 10 μm is prepared. The prepared 50 g of yttria stabilized zirconia nanoparticle powder and 50 g of tourmaline particles are mixed using a high speed stirring dispersion device.
상기 혼합물에 점착용 바인더인 Acrylic Polymer, Ethyl Acetate를 각각 450g씩 첨가하고, 적정량(9~18g)의 경화제를 첨가하고 교반하여 근골격계 질환 치료용 지르코니아 테이프 원료를 제조한다.450 g of acrylic polymer and ethyl acetate, which are adhesive binders, are added to the mixture, and an appropriate amount (9-18 g) of a curing agent is added and stirred to prepare a zirconia tape raw material for treating musculoskeletal disorders.
위 원료를 코팅대에 올려놓고 이형지에 허가량 만큼의 양(50g/m2)을 넓게 펼쳐 바른다.Place the above raw materials on the coating table and spread the amount (50g / m 2 ) on the release paper as much as the approved amount.
120℃의 건조기를 통과시켜 건조시킨다.Dry by passing through a dryer at 120 ° C.
규격대로 재단한 후 60℃ 숙성실에서 48시간 숙성시킨다. After cutting according to the standard, it is aged for 48 hours at 60 ℃ aging room.
상기 점착용 바인더와 경화제는 아크릴 폴리머, 경화제인 이소시아네이트계 화합물, NCO화합물 35~50%, 에틸아세테이트 50~70%와 같은 치료테이프용 점착 바인더와 경화제로서 규제를 만족하는 바인더라면 제조방법과 관계없이 본 발명에서 사용이 가능하다.
The adhesive binder and the curing agent are adhesive tapes for curing tapes such as acrylic polymers, isocyanate compounds which are curing agents, 35 to 50% of NCO compounds, and 50 to 70% of ethyl acetate, and binders satisfying the regulations as curing agents regardless of the manufacturing method. It is possible to use in the present invention.
Claims (8)
b) 기능성 충진제 분말인 입경이 1~2nm인 은, 백금, 및 입경이 0.1~100㎛인 토르말린 입자들 중 하나 이상을 상기 지르코니아 입자와 함께 점착용 바인더에 투입하여 분산시켜 상기 지르코니아와 상기 은 또는 백금 또는 토르말린 입자가 고르게 분산 혼합된 세라믹 복합체 혼합물을 형성하는 단계(S20)와,
c) 상기 b)단계에 제조된 세라믹 복합체 혼합물에 경화제를 교반하여 혼합시키는 단계(S30)와,
d) 상기 경화제가 첨가되어 교반된 상기 세라믹 복합체를 이형지에 균일하게 도포하고 건조시킨 후 테이프용 면직물에 도포시키는 단계(S40)와,
e) 상기 d) 단계에서 형성된 테이프를 재단하여 숙성시키는 단계(S50)를 포함하는 근골격계 질환 치료보조용 지르코니아 테이프제조방법.
a) preparing a zirconia particle having a particle diameter of 20 to 50 nm and stabilized with yttria (S10);
b) at least one of silver, platinum, and tourmaline particles having a particle size of 1 to 2 nm, which are functional filler powders, and particles having a particle size of 0.1 to 100 μm, are dispersed together with the zirconia particles in an adhesive binder to disperse the zirconia and the silver or (S20) forming a ceramic composite mixture in which the platinum or tourmaline particles are evenly dispersed and mixed;
c) mixing and stirring a curing agent to the ceramic composite mixture prepared in step b) (S30),
d) applying the cured agent to the stirred agitated ceramic composite uniformly on a release paper and dried and then applying it to a cotton fabric for tape (S40),
e) a method of producing zirconia tape for treating musculoskeletal disorders, comprising the step (S50) of cutting and aging the tape formed in step d).
상기 a) 단계(S10)는,
중량비가 90:10 내지 98:2가 되도록 ZrOCl2ㆍ8H20와 YClㆍ6H20의 혼합물을 각각의 중량이 반응과는 무관한 물과 수산화칼륨의 혼합용액에 혼합하는 단계(S11)와,
상기 혼합용액을 150 내지 200℃의 온도에서 24시간 가열하여 이트리아에 의해 표면이 안정화된 슬러리 상태의 지르코니아를 획득하는 단계(S12)와,
상기 슬러리상의 지르코니아를 세정 및 필터링하여 습체 상태의 이트리아로 안정화된 입경이 20 내지 50nm인 지르코니아를 획득하는 단계(S13) 및,
상기 습체 상태의 지르코니아를 100℃에서 24시간 건조시켜 이트리아로 표면이 안정화되며, 20 ~ 50nm 입경의 지르코니아 입자를 획득하는 단계(S14)를 포함하는 근골격계 질환 치료보조용 지르코니아 테이프 제조방법.
The method of claim 1,
Step a) (S10),
And 2 so that it ZrOCl 2 8H 2 0 and with YCl and 6H 2 0 mixture by weight of each of the steps (S11) to the reaction mixture and is a mixed solution of water and potassium are independent of the weight ratio is 90: 10 to 98 ,
Heating the mixed solution at a temperature of 150 to 200 ° C. for 24 hours to obtain zirconia in a slurry state whose surface is stabilized by yttria (S12);
Washing and filtering the slurry-like zirconia to obtain zirconia having a particle size of 20 to 50 nm stabilized with yttria in a wet state (S13);
Method of producing a zirconia tape for treating musculoskeletal disorders comprising the step (S14) of stabilizing the surface with yttria by drying the wet zirconia at 100 ° C. for 24 hours and obtaining zirconia particles having a particle size of 20 to 50 nm.
상기 b) 단계(S20)에서,
상기 이트리아로 안정화된 지르코니아 입자 및 토르말린 입자의 혼합분말의 중량비는 70:30 내지 50:50이며, 상기 혼합분말에서 기능성 충전제로 은 입자, 백금입자를 첨가할 경우 총 혼합분말의 중량을 100중량비로 할 때 상기 이트리아로 안정화된 지르코니아 입자, 은 입자, 백금 입자, 토르말린 입자의 중량비는 70:5:5:20 내지 50:0.001:0.001:49.998 인 것을 특징으로 하는 근골격계 질환 치료보조용 지르코니아 테이프 제조방법.
The method according to claim 1 or 2,
In step b) (S20),
The weight ratio of the mixed powder of the zirconia particles and the tourmaline particles stabilized with yttria is 70:30 to 50:50, and when the silver particles and platinum particles are added as functional fillers in the mixed powder, the weight of the total mixed powder is 100% by weight. When the weight ratio of the yttria stabilized zirconia particles, silver particles, platinum particles, tourmaline particles is 70: 5: 5: 20 to 50: 0.001: 0.001: 49.998 zirconia tape for the treatment of musculoskeletal disorders, characterized in that Manufacturing method.
The method of claim 3, wherein the weight ratio of the mixed powder of the zirconia particles and the tourmaline particles stabilized with yttria is 55:45.
The method of claim 3, wherein the weight ratio of the yttria stabilized zirconia particles, silver particles, platinum particles, tourmaline particles is 55: 0.1: 0.1: 44.8.
상기 b) 단계(S20)의 상기 점착용 바인더는 Acrylic Polymer, Ethyl Acetate, PVB(PolyVinyl Butyral), PVP(PolyVinyl Pyrrolidone), PVA(PolyVinyl Acetate) 및 PEG(Polythylene Glycol) 중 선택된 하나이며, 상기 혼합분말 2 내지 10wt%에 대하여 90 ~ 98 wt%의 중량비로 첨가하는 것을 특징으로 하는 근골격계 질환 치료용 지르코니아 테이프 제조방법.
The method of claim 3,
The adhesive binder in step b20 is one selected from Acrylic Polymer, Ethyl Acetate, PolyVinyl Butyral (PVB), PolyVinyl Pyrrolidone (PVP), PolyVinyl Acetate (PVA), and Polyethylene Glycol (PEG), and the mixed powder Method for producing zirconia tape for treating musculoskeletal disorders, characterized in that it is added in a weight ratio of 90 to 98 wt% relative to 2 to 10wt%.
50 to 70 wt% of zirconia particles having a particle diameter of 20 to 50 nm stabilized with yttria, 5 wt% to 0.001 wt% of silver or platinum particles each having a particle diameter of 1 to 2 nm bonded to the surface of the zirconia, and the silver and platinum particles Ceramic composite consisting of 20 to 49.998 wt% of tourmaline particles having a particle size of 0.1 to 100 μm mixed with the zirconia particles bonded to the surface, 90 to 98 wt% of the pressure-sensitive adhesive and the ceramic to which 2 to 10 wt% of the ceramic composite are dispersed Zirconia tape for the treatment of musculoskeletal disorders comprising a curing agent added to the mixture of the composite and the adhesive in a weight ratio of about 1.8 to 3.8 wt%.
상기 지르코니아 입자는 2~10wt%의 이트리아로 안정화된 것을 특징으로 하는 근골격계 질환 치료보조용 지르코니아 테이프.The method of claim 7, wherein
The zirconia particles are zirconia tape for the treatment of musculoskeletal disorders, characterized in that stabilized with 2 ~ 10wt% yttria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100015166A KR101059844B1 (en) | 2010-02-19 | 2010-02-19 | Functional assistant tape for treating musculoskeletal using zirconia and method for manufacturing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100015166A KR101059844B1 (en) | 2010-02-19 | 2010-02-19 | Functional assistant tape for treating musculoskeletal using zirconia and method for manufacturing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110095602A KR20110095602A (en) | 2011-08-25 |
| KR101059844B1 true KR101059844B1 (en) | 2011-08-30 |
Family
ID=44933835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100015166A KR101059844B1 (en) | 2010-02-19 | 2010-02-19 | Functional assistant tape for treating musculoskeletal using zirconia and method for manufacturing the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101059844B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102145997B1 (en) * | 2018-05-25 | 2020-08-20 | 창원대학교 산학협력단 | Organic/inorganic hybrid thin co mprising Ag doped YSZ film for antimicrobial activity and fabrication thereof |
| CN113134110B (en) * | 2020-01-16 | 2023-02-21 | 广州增城潮徽生物技术有限公司 | PVP/PVB slow-release nano-fiber medical dressing and preparation method and application thereof |
-
2010
- 2010-02-19 KR KR1020100015166A patent/KR101059844B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110095602A (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106729927B (en) | Modified bioactive glass/polyacrylamide/oxidized sodium alginate hydrogel dressing and preparation method thereof | |
| Taghizadeh et al. | Mussel‐inspired biomaterials: From chemistry to clinic | |
| CN1625624A (en) | Method for hydrophilizing materials using hydrophilic polymeric materials with discrete charges | |
| CN1809390A (en) | Wound dressing and wound dressing kit | |
| Liu et al. | Template-assisted magnetron sputtering of cotton nonwovens for wound healing application | |
| JP7503814B2 (en) | Hemostatic composite and method for producing same | |
| KR101059844B1 (en) | Functional assistant tape for treating musculoskeletal using zirconia and method for manufacturing the same | |
| KR20170045007A (en) | Products comprising shungite and method for manufacturing the same | |
| CN107201124A (en) | A kind of water-borne acrylic coatings of utilization anion fine-purification air | |
| CN111228484B (en) | Application of xonotlite and composite biological material containing xonotlite | |
| CN110003660A (en) | A kind of Terahertz material silica gel composite and preparation method thereof | |
| CN1923294A (en) | Composition with antibiotic, deodorant and air purifying function and its preparing process and use | |
| Al-Ahmed et al. | Electrospun nanofibrous scaffolds of ε-polycaprolactone containing graphene oxide and encapsulated with magnetite nanoparticles for wound healing utilizations | |
| CN110041706A (en) | Terahertz silica gel material | |
| CN113026198A (en) | Functional dressing and preparation method thereof | |
| Tang et al. | Development of an Antioxidant and UV-Shielding Composite Hydrogel Using Mussel-Inspired Cellulose Nanocrystals, Polydopamine, and Poly (vinyl alcohol) for Application in Sunscreens | |
| CN110960352B (en) | Intelligent dressing and preparation method thereof | |
| US20210007942A1 (en) | Method for color maintenance and enhancement of tattoo | |
| US7645915B2 (en) | Composite dressing | |
| CN108135861A (en) | Dry type is pasted | |
| KR20230118479A (en) | Manufacturing method of antibacterial fiber using scallop firing powder | |
| KR20060129593A (en) | Natural mineral composition coated on filter member and method for manufacturing functional environment-friendly filter member thereof and its filter member | |
| WO2019056819A1 (en) | Collagen-loaded alginate medical dressing and preparation method therefor | |
| CN104233812A (en) | Preparation method of medical cotton cloth with sterilization, disinfection and healing promoting functions | |
| KR101053781B1 (en) | Eco-friendly functional paint and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |